VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
IRWD
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
IRWDIronwood Pharmaceuticals, Inc.
$4.30$708M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksIRWDCash Flow

Ironwood Pharmaceuticals, Inc. (IRWD) Cash Flow Statement

19Y historyFree accessUpdated daily

Free cash flow generation is highly inconsistent, evidenced by a volatile FCF margin that fluctuated from a negative 17.7% in 2025Q2 to a peak of 156.3% in 2025Q4.

IRWD Cash Flow Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07
Cash from Operations112.21M127.04M103.55M183.43M273.76M261.89M168.84M10.72M-70.88M-99.56M-25.43M-106.93M-155.57M-273.36M-69.63M-75.24M-67.9M-4M-28.2M-6.76M
Operating CF Margin %-42.9%29.47%41.43%66.67%63.3%43.34%2.5%-20.45%-33.38%-9.28%-71.5%-203.53%-1194.68%-46.35%-114.22%-154.82%-11.07%-126.91%-64.59%
Operating CF Growth %552.18%22.69%-43.55%-33%4.53%55.12%1474.23%115.13%28.81%-291.47%76.21%31.27%43.09%-292.57%7.45%-10.81%-1598.32%85.82%-317.15%-
Net Income102.18M24.02M880K-1B175.06M528.45M106.18M21.5M-282.37M-116.94M-81.71M-142.67M-189.62M-272.81M-72.62M-64.85M-56.41M-73.31M-55.03M-53.16M
Depreciation & Amortization2.79M1.88M2.01M1.57M1.42M1.5M3.56M5.58M14.22M14.62M11.26M11.63M12.33M11.73M11.32M10M6.16M5.25M2.85M1.73M
Stock-Based Compensation20.09M17.25M29.85M32.01M27.05M22.28M31.18M31.28M43.98M33.82M29.22M25.47M26.18M19.83M17.57M11.73M7.5M5.24M2.79M1.15M
Deferred Taxes101.2M40.8M68.09M72.64M65.74M-333.29M6.6M0159.11M7.53M-7.31M28.48M21.5M1.86M07K-5.5M970K-1K-1K
Other Non-Cash Items-107.5M3.44M1.98M1.07B1.67M25.23M22.26M52.35M-13.44M-16.81M28.12M8.4M4.14M1.72M1.18M2.23M1.62M-360K532K-1.72M
Working Capital Changes-70.23M39.65M739K11.28M2.82M17.73M-941K-99.99M7.62M-21.79M-5.02M-38.24M-30.1M-35.68M-27.08M-34.36M-21.27M58.21M20.66M45.24M
Change in Receivables-66.07M35.15M47.24M924K7.99M7.71M4.09M-68.89M1.21M-17.3M-10.34M-28.68M-23.68M-1.73M-835K2.24M2.32M-465K18.39M-24.28M
Change in Inventory000000648K0-806K346K1.27M3.65M-3.08M-11.91M-6.7M1.29M-9.26M1.71M00
Change in Payables-8.35M6.2M-20.21M12.38M-8.12M-2.64M-7.52M-32.7M8.06M-6.84M19.68M-1.55M1.43M-11.72M24.24M5.09M2.74M1.57M00
Cash from Investing-3K-34K-142K-1.03B-136K-265K-1.84M-11.14M88.87M151.46M-177.67M-9.15M-56.57M-101.43M30.08M115.06M-213.04M17.76M-15.07M-27.61M
Capital Expenditures-7K-34K-142K-273K-136K-265K-1.84M-7.19M-8.62M-4.21M-104.21M-4.05M-3.54M-9.59M-13.98M-9.68M-17.22M-4.04M-22.93M-2.65M
CapEx % of Revenue0%0.01%0.04%0.06%0.03%0.06%0.47%1.68%2.49%1.41%38.04%2.71%4.63%41.92%9.3%14.7%39.26%11.2%103.23%25.33%
Acquisitions000-1.03B00001.56M135K100M147K00009.5M000
Investments--------------------
Other Investing4K000000-3.96M1.56M135K-99.78M147K-53.03M-91.84M9K4K2K21K9K1K
Cash from Financing210K216K-106.97M277.16M-237.55M-4.55M18.55M-1.19M30.07M19.84M-4.18M303.07M210.94M313.58M88.97M3.13M202.96M41.66M48.56M50.72M
Debt Issued (Net)00-115M300M-120.7M0019.43M-1.82M8.76M-28.77M321.67M-2.23M174.23M-275K-260K-1.96M1.14M-1.22M720K
Equity Issued (Net)210K216K11.01M6.36M-126.39M-24.13M18.55M00000190.43M137.77M85.23M0203.17M40.25M49.6M49.95M
Dividends Paid00000000000000000000
Share Repurchases0000-126.39M-24.13M00000000000000
Other Financing00-2.98M-29.2M9.54M19.58M0-20.61M31.9M11.08M24.59M-18.6M22.74M1.58M4.02M3.39M1.75M272K180K47K
Net Change in Cash111.99M126.9M-3.6M-565.78M36.07M257.08M185.54M-1.6M48.06M71.73M-207.28M186.99M-1.19M-61.21M49.42M42.96M-77.98M55.42M5.29M16.35M
Free Cash Flow112.21M127.01M103.41M183.15M273.63M261.63M166.99M3.54M-79.5M-103.77M-129.64M-110.98M-159.11M-282.95M-83.61M-84.92M-85.12M-8.04M-51.13M-9.41M
FCF Margin %31.04%42.89%29.43%41.37%66.64%63.23%42.87%0.83%-22.94%-34.79%-47.32%-74.2%-208.16%-1236.6%-55.65%-128.92%-194.08%-22.28%-230.14%-89.93%
FCF Growth %43.1%22.83%-43.54%-33.06%4.59%56.67%4622.68%104.45%23.39%19.95%-16.82%30.25%43.77%-238.4%1.54%0.24%-958.3%84.27%-443.35%-
FCF per Share0.670.710.651.181.471.591.040.02-0.52-0.70-0.89-0.78-1.16-2.44-0.79-0.85-0.95-0.12-0.73-0.12
FCF Conversion (FCF/Net Income)1.10x5.29x117.67x-0.18x1.56x0.50x1.59x0.50x0.25x0.85x0.31x0.75x0.82x1.00x0.96x1.16x1.28x0.06x0.52x0.13x
Interest Paid0032.56M13.55M5.75M7.22M7.22M17.58M0000000-64K0412K00
Taxes Paid008.41M9.95M4.62M3.45M1.85M00000000-3K0153K00

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetAdequate
Cash FlowMixed
Top Statement Risk

Single-product revenue concentration

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings and Cash Flow Decoupling

As reported in financial statements, Ironwood's operating cash flow frequently diverges from net income, evidenced by a volatile OCF/NI ratio that reached a negative 32.77 in 2025Q4, suggesting that accounting accruals and collaboration profit-sharing mechanics significantly distort the company's underlying cash-generating capability on a quarterly basis.

The extreme variance between net income and operating cash flow indicates that reported earnings are not a reliable proxy for actual liquidity. Investors should monitor these fluctuations as they appear to be driven by the timing of collaboration payments and working capital adjustments rather than core operational performance.

Inconsistent Free Cash Flow Generation

Based on recent SEC filings, Ironwood's free cash flow trajectory remains highly erratic, with margins swinging from a negative 17.7% in 2025Q2 to a peak of 156.3% in 2025Q4, highlighting the inherent instability of a business model tethered to lumpy collaboration-based revenue streams and variable operating expenses.

The lack of a stable FCF trend suggests that the company's cash generation is highly sensitive to the timing of partnership settlements. This volatility complicates long-term valuation, as the business appears unable to maintain consistent cash conversion across consecutive reporting periods.

Working Capital Volatility Impacts Liquidity

According to historical cash flow data, working capital changes have been a primary driver of liquidity swings, including a significant $73.5 million inflow in 2025Q4 followed by a $59.8 million outflow in 2026Q1, indicating that the company's cash position is heavily influenced by timing differences in receivables.

These sharp reversals in working capital suggest that the company's cash flow is subject to the payment cycles of its commercial partners. Such instability warrants further investigation into whether these movements represent structural shifts in collection efficiency or merely the episodic nature of profit-sharing distributions.

Hidden Costs of Stock Compensation

As disclosed in recent financial statements, Ironwood consistently utilizes stock-based compensation, with expenses reaching $12.0 million in 2025Q4, which effectively masks the true economic cost of operations by excluding these non-cash charges from the company's reported operating cash flow figures and overall profitability metrics.

The reliance on stock-based compensation suggests that the company may be managing its cash burn by substituting equity for cash-based incentives. Investors should consider the dilutive impact of these practices, as they represent a real cost to shareholders that is not fully captured in the headline cash flow statements.

IRWD — Frequently Asked Questions

Quick answers to the most common questions about buying IRWD stock.

How much cash does Ironwood Pharmaceuticals, Inc. (IRWD) generate from operations?

Ironwood Pharmaceuticals, Inc. (IRWD) generated $127.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Ironwood Pharmaceuticals, Inc.'s free cash flow?

Ironwood Pharmaceuticals, Inc. (IRWD) generated $127.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.

What is Ironwood Pharmaceuticals, Inc.'s capital expenditure (CapEx)?

Ironwood Pharmaceuticals, Inc. (IRWD) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.